NYT: Alzheimer’s Drug Shows Promise in Small Trial

An Alzheimer’s drug manufactured by Eli Lilly has shown to slow down the rate that patients lose their ability to think and care for themselves. This was a small clinical trial with 272 patients and has not yet been published or widely reviewed. However, if the findings are true, then this would be the first drug to have a positive outcome in Phase 2 trials. Other Alzheimer’s drugs were never tested in Phase 2 because they either moved straight into Phase 3 or didn’t have positive results. Participants in the study showed the rate of decline to slow by 32% compared to patients who received the placebo. Click here to read the full article by Gina Kolata.